Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.
| Revenue (TTM) | $539.57M |
| Gross Profit (TTM) | $402.91M |
| EBITDA | $-3.46M |
| Operating Margin | -9.53% |
| Return on Equity | -9.92% |
| Return on Assets | -4.02% |
| Revenue/Share (TTM) | $50.03 |
| Book Value | $7.49 |
| Price-to-Book | 2.30 |
| Price-to-Sales (TTM) | 0.34 |
| EV/Revenue | 1.478 |
| EV/EBITDA | -0.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.20% |
| Shares Outstanding | $8.81M |
| Float | $44.05M |
| % Insiders | 4.01% |
| % Institutions | 45.79% |
Volatility is currently contracting